World’s first in vivo gene editing Phase 3 win (opens in new tab)

A one-time CRISPR treatment dramatically reduced attacks in hereditary angioedema, marking a major milestone for genetic medicine. Gene editing has been generating headlines, hope and skepticism in roughly equal measure. Last weekend, it delivered something tangible: a Phase 3 clinical success. Intellia Therapeutics announced additional positive results from its HAELO Phase 3 trial of lonvoguran […] The post appeared first on <a href="